BLOOMFIELD, N.J., Feb. 9 /PRNewswire/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease (RNase) therapeutics for cancer and other life-threatening diseases, today announced that Kuslima Shogen, Chairman and Chief Executive Officer, will present at the 8th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York on Tuesday, February 14 at 4:00PM EST.
Dr. Shogen will participate in the Focus Session entitled, “Cancer: New Mechanisms of Action for Cancer Treatment.” The panel will examine a number of emerging approaches based on new mechanisms involved in cancer, as well as some of the key challenges ahead. Among the approaches to be discussed is the groundbreaking RNase technology platform developed by Alfacell.
For more information about the conference, visit www.bio.org.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other diseases, using its ribonuclease (RNase) technology platform. ONCONASE(R) (ranpirnase), Alfacell’s lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I/II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.comacel@efcg.net
Alfacell Corporation
CONTACT: Kuslima Shogen or Robert Love, both of Alfacell Corporation,+1-973-748-8082, info@alfacell.com; or Investor/Media Relations, Dodi Handyof Elite Financial Communications, +1-407-585-1080, acel@efcg.net, forAlfacell Corporation
